Pauline Parent
YOU?
Author Swipe
View article: Efficacy of immunotherapy in gastrointestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype: an AGEO real-world study
Efficacy of immunotherapy in gastrointestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype: an AGEO real-world study Open
Background Tumors with mismatch repair deficiency (MMRd) classically display concomitant loss of MLH1/PMS2 or MSH2/MSH6 on immunohistochemistry (IHC) with microsatellite instability-high (MSI-High) status on molecular testing. Nevertheless…
View article: Muscle Loss During First‐Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity
Muscle Loss During First‐Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity Open
Background Advanced pancreatic ductal adenocarcinoma (aPDAC) is often accompanied by significant muscle mass loss, contributing to poor prognosis. SarcAPACaP, an ancillary study of the GERCOR‐APACaP phase III trial, evaluated the role of a…
View article: Prognostic Impact of the Braf V600e Mutation in Patients with Msi-High Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Prognostic Impact of the Braf V600e Mutation in Patients with Msi-High Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors Open
View article: Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors Open
Background Immune checkpoint inhibitors (ICIs) are recommended to treat patients with deficient mismatch repair/microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC). Pivotal trials have fixed a maximum ICI durat…
View article: Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors
Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors Open
Background: Immune checkpoint inhibitors (ICIs) improve overall survival (OS) in advanced/metastatic urothelial cancer (a/mUC) patients. Preliminary evidence suggests a prognostic role of inflammatory biomarkers in this setting. We aimed t…
View article: Braf + Egfr +/- Mek Inhibitors after Immune Checkpoint Inhibitors In Braf V600e Mutated and Deficient Mismatch Repair or Microsatellite Instability High Metastatic Colorectal Cancer
Braf + Egfr +/- Mek Inhibitors after Immune Checkpoint Inhibitors In Braf V600e Mutated and Deficient Mismatch Repair or Microsatellite Instability High Metastatic Colorectal Cancer Open
View article: Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor
Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor Open
View article: Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma
Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma Open
Few prognostic factors have been identified in patients with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibitors (ICIs). The Lung Immune Prognostic Index (LIPI) was associated with clinical outcomes for ICIs in …
View article: Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer
Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer Open
Immune checkpoint inhibitors (ICIs) are commonly used to treat patients with advanced urothelial cancer. However, a significant number of patients do not respond to ICI, and the lack of validated predictive biomarkers impedes the success o…
View article: Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study
Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study Open
Introduction Less than one-third of bladder cancers are non-pure urothelial carcinoma [with variant histological (VH) or non-urothelial carcinoma (non-UC)] for which no treatment guidelines are available. We aim to evaluate the efficacy of…
View article: A comprehensive overview of promising biomarkers in stage II colorectal cancer
A comprehensive overview of promising biomarkers in stage II colorectal cancer Open
International audience
View article: New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?
New rising entities in cancer of unknown primary: Is there a real therapeutic benefit? Open